July 29, 2016 11:08 PM ET

Biotechnology

Company Overview of Applied Genetic Technologies Corporation

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops gene therapy products to treat patients with severe inherited orphan diseases in ophthalmology in the United States. The company’s lead product candidates include treatments for X-linked retinoschisis, achromatopsia, and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye caused by mutations in single genes. It is also developing adeno-associated virus based gene therapies for the treatment of rare eye diseases; and a product candidate for treatment of alpha-1 antitrypsin deficiency for which it has conducted preclinical proof-of-concept studies and Phase I and Phase II clinic...

11801 Research Drive

Suite D

Alachua, FL 32615

United States

Founded in 1999

35 Employees

Phone:

386-462-2204

Key Executives for Applied Genetic Technologies Corporation

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $400.0K
Chief Financial Officer
Age: 60
Total Annual Compensation: $300.0K
Chief Medical Officer and Vice President
Age: 69
Total Annual Compensation: $350.0K
Chief Business Officer and Vice President
Age: 60
Total Annual Compensation: $127.1K
Chief Scientific Officer
Age: 56
Total Annual Compensation: $79.2K
Compensation as of Fiscal Year 2015.

Applied Genetic Technologies Corporation Key Developments

Applied Genetic Technologies Corporation - Shareholder/Analyst Call

Applied Genetic Technologies Corporation - Shareholder/Analyst Call

Applied Genetic Technologies Corporation Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 through Jul-13-2016

Applied Genetic Technologies Corporation Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-12-2016 through Jul-13-2016. Venue: Le Parker Meridien, New York, New York, United States. Presentation Date & Speakers: Jul-13-2016, Mark S. Shearman, Chief Scientific Officer, Stephen W. Potter, Chief Business Officer and Vice President.

Applied Genetic Technologies Corporation Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation announced that the European Commission (EC) has granted an orphan medicinal product designation to its investigational gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. Preclinical data indicate that treatment with a gene therapy product slowed the loss of visual function in canines with XLRP caused by mutations in the RPGR gene.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Applied Genetic Technologies Corporation, please visit www.agtc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.